tradingkey.logo

Tourmaline soars after Novartis to acquire co for $1.4 billion

ReutersSep 9, 2025 2:15 PM

Shares of biotech firm Tourmaline TRML.O soar 57.8% to $47.62, hitting their highest since March 2024, after Novartis NOVN.S said it will acquire co in $1.4 bln cash deal

NOVN to pay $48 per share, representing premium of 59% to TRML's last close of $30.18

As of Monday's close, TRML is valued at $775.4 million, according to data compiled by LSEG

Deal expected to close in Q4, TRML will become indirect, wholly owned subsidiary of NOVN

TRML is focused on developing pacibekitug, targeted therapy with potential to reduce systemic inflammation, as treatment option for atherosclerotic cardiovascular disease

Including session's move, TRML up about 134% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI